Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

March 26, 2024

https://www.globenewswire.com/news-release/2024/03/26/2852194/0/en/Beam-Therapeutics-Announces-Clearance-of-Clinical-Trial-Authorisation-Application-for-BEAM-302-for-the-Treatment-of-Alpha-1-Antitrypsin-Deficiency-AATD.html

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with alpha-1 antitrypsin deficiency (AATD).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.